

Impact of microparticle-based drug delivery systems on patient adherence in diabetes management: A literature-based perspective

Marewad Shilpa Jalindar^{1*}, Dr. Tushar Treembak Shelke²

1 Research Scholar, Sunrise University, Alwar, Rajasthan, India

marewadshilpa@gmail.com

2 Professor, Department of Pharmaceutical Sciences, Sunrise University, Alwar, Rajasthan, India

Abstract: Diabetes mellitus represents a major chronic health condition requiring sustained pharmacological intervention, where patient adherence plays a critical role in determining therapeutic success. This study examines the impact of microparticle-based drug delivery systems on patient adherence in diabetes management, with particular emphasis on Metformin formulations using PLGA (Poly(lactic-co-glycolic acid)). The prime aim of the study is to critically evaluate how controlled-release microparticle systems influence adherence by reducing dosing frequency, improving tolerability, and enhancing overall patient acceptance.

The research adopts a qualitative, literature-based methodology relying exclusively on secondary data sources, including peer-reviewed open-access journal articles, clinical reports, and pharmaceutical studies. A thematic and comparative synthesis is conducted to analyze adherence patterns, pharmacokinetic behavior, formulation characteristics, and patient-reported outcomes associated with microparticle-based systems.

The findings indicate that sustained-release microparticle formulations significantly improve patient adherence by stabilizing plasma drug levels, minimizing gastrointestinal side effects, and simplifying dosing regimens. PLGA-based systems demonstrate high formulation stability, biocompatibility, and consistent drug release, contributing to improved therapeutic outcomes. The study also highlights that integrating pharmaceutical design with patient-centered considerations is essential for achieving long-term treatment compliance.

The study concludes that microparticle-based drug delivery systems offer a promising approach to overcoming adherence challenges in diabetes management. However, further clinical validation and integration with patient-focused healthcare strategies are necessary to maximize their real-world applicability.

Keywords: Microparticle drug delivery, Patient adherence, PLGA, Metformin, Controlled release

1. INTRODUCTION

Diabetes mellitus continues to impose a substantial global health burden, requiring long-term pharmacological intervention and continuous disease monitoring. The chronic nature of the disease demands sustained patient engagement with therapeutic regimens, making medication adherence a critical determinant of treatment success. Poor adherence has been consistently linked with suboptimal glycemic control, increased complications, and higher healthcare costs (Polonsky & Henry, 2016). Among oral anti-diabetic agents, Metformin remains the cornerstone of therapy due to its proven efficacy and safety profile. However, conventional delivery systems often fail to address adherence-related challenges. In this context, microparticle-based drug delivery systems have emerged as an innovative pharmaceutical approach designed to enhance drug performance and improve patient compliance through controlled and sustained release (Villasaliu et al., 2014).

The development of oral drug delivery systems has evolved significantly from immediate-release formulations to advanced controlled-release technologies aimed at improving therapeutic efficiency. Polymer-based microparticles represent a key advancement in this progression, offering the ability to modulate drug release profiles and enhance stability. Among these, PLGA (Poly(lactic-co-glycolic acid)) has gained prominence due to its biodegradability, biocompatibility, and regulatory acceptance. Its application in oral therapy has enabled improved pharmacokinetic control and reduced dosing frequency. The shift toward patient-centric formulation design reflects the growing recognition that pharmaceutical innovation must align with patient behavior and preferences to achieve optimal outcomes (Peppas et al., 2016).

Despite advancements in pharmacotherapy, medication adherence in diabetes management remains a persistent challenge. Frequent dosing schedules, gastrointestinal side effects, and complex treatment regimens contribute significantly to non-compliance. Conventional drug delivery systems often overlook behavioral aspects of therapy, focusing primarily on pharmacological efficacy. This disconnect between formulation science and patient experience underscores the need for adherence-oriented drug delivery systems. Microparticle-based formulations offer potential solutions by simplifying dosing regimens and minimizing adverse effects, thereby addressing both pharmacological and behavioral barriers (Shrivastava et al., 2013).

Recent developments in pharmaceutical sciences have emphasized the importance of sustained-release and smart drug delivery technologies. The integration of patient-reported outcomes (PROs) into drug development processes reflects a shift toward evaluating therapeutic success beyond clinical parameters. Advances in polymer science have facilitated the development of sophisticated microparticle systems capable of targeted and controlled drug delivery. Additionally, regulatory frameworks are increasingly encouraging the development of patient-centric formulations that improve adherence and overall treatment outcomes (Costa et al., 2019).

The conceptual framework of this study establishes a direct linkage between formulation design and patient adherence. It proposes that optimized microparticle formulations influence drug release profiles, which in turn reduce side effects and dosing frequency. These improvements positively affect patient adherence, ultimately leading to enhanced therapeutic success. The framework integrates pharmaceutical properties such as release kinetics and stability with behavioral outcomes, emphasizing the importance of aligning pharmacokinetics with patient compliance patterns.

A study by Krass et al. (2015) aimed to evaluate adherence levels among patients using modified-release formulations and employed observational and survey-based methodologies. The findings revealed that reduced dosing frequency significantly improved adherence, highlighting the importance of sustained-release systems. Another study conducted by McCreight et al. (2016) examined the tolerability of metformin formulations through clinical evaluation and reported that modified-release formulations were associated with fewer gastrointestinal side effects, leading to better patient acceptance. In a systematic review, Kardas et al. (2013) investigated the relationship between drug delivery systems and patient behavior, concluding that simplified treatment regimens positively influenced adherence. Additionally, research by Kumari et al. (2010) explored polymer-based drug delivery systems and demonstrated that microparticle formulations improved therapeutic outcomes in chronic disease management by providing controlled drug release and enhanced patient compliance.

Existing literature reveals a lack of comprehensive integration between microparticle-based drug delivery systems and patient adherence outcomes. There is limited synthesis of patient-reported outcomes with pharmaceutical formulation design, and long-term adherence

studies remain insufficient. Furthermore, the absence of standardized comparative frameworks restricts the ability to evaluate the effectiveness of different delivery systems across studies.

This study aims to critically evaluate the impact of microparticle-based drug delivery systems on patient adherence in diabetes management through a comprehensive literature-based analysis, focusing on formulation characteristics, pharmacokinetic advantages, and patient-centered outcomes.

This study has adopted a qualitative, literature-based research methodology relying exclusively on secondary data sources. Relevant information was systematically collected from open-access scientific journals, clinical reports, and pharmaceutical databases. The collected data were categorized into key themes including adherence patterns, pharmacokinetics, and formulation strategies. A comparative and thematic analysis was conducted to synthesize findings across studies, enabling a critical evaluation of the role of microparticle-based systems in improving patient adherence in diabetes management.

2. MICROPARTICLE-BASED DRUG DELIVERY AND ADHERENCE DYNAMICS

Fundamentals of Patient Adherence in Diabetes

Patient adherence refers to the extent to which individuals follow prescribed therapeutic regimens in terms of dosage, timing, and frequency. In diabetes management, adherence is essential because the disease requires long-term pharmacological intervention combined with lifestyle modifications. Adherence is influenced by multiple determinants, including clinical factors such as disease severity, behavioral aspects such as patient motivation and awareness, and economic conditions such as treatment cost and accessibility (Jimmy & Jose, 2011). Nonadherence leads to poor glycemic control, increased risk of complications, and higher healthcare expenditure. It also contributes to frequent hospitalizations and reduced quality of life, making adherence a central concern in chronic disease management (Brown & Bussell, 2011).

Pharmaceutical Basis of Microparticle Drug Delivery

Microparticle-based drug delivery systems consist of polymeric carriers that encapsulate active pharmaceutical ingredients within a matrix or core-shell structure. These systems are classified into microspheres and microcapsules based on their structural characteristics. In oral drug

delivery, microparticles protect the drug from degradation in the gastrointestinal environment and facilitate controlled release. Their ability to modulate drug release profiles is particularly valuable for chronic conditions such as diabetes, where maintaining stable drug levels is critical. The mechanisms of controlled release involve diffusion, polymer swelling, and degradation processes, which collectively regulate the rate and extent of drug availability in the systemic circulation (Danhier et al., 2012).

Influence of Controlled Release on Adherence

Controlled-release formulations significantly influence patient adherence by reducing the frequency of drug administration. When drugs are delivered through sustained-release systems, they maintain stable plasma concentrations over extended periods, minimizing fluctuations associated with immediate-release formulations. This stabilization improves therapeutic consistency and reduces the likelihood of missed doses. For patients managing diabetes, simplified dosing schedules reduce treatment burden and enhance compliance. Consequently, controlled-release systems contribute to improved clinical outcomes by ensuring continuous drug action (Lee et al., 2015).

Formulation Convenience and Patient Acceptance

Convenience of drug formulation plays a vital role in determining patient acceptance and adherence. Microparticle-based systems often reduce pill burden by enabling once-daily or less frequent dosing, which aligns better with patients' daily routines. Ease of administration minimizes disruption to lifestyle and improves the overall treatment experience. Patients are more likely to adhere to therapies that are simple, less intrusive, and compatible with their daily activities. Positive perception of formulation convenience enhances trust in the treatment and encourages long-term compliance (Osterberg & Blaschke, 2005).

Tolerability and Side-Effect Reduction

Tolerability is a critical factor influencing adherence, particularly in oral anti-diabetic therapy. Conventional formulations of drugs such as Metformin are often associated with gastrointestinal side effects that lead to treatment discontinuation. Microparticle-based delivery systems help minimize such adverse effects by controlling the rate of drug release and reducing peak plasma concentrations. This gradual release reduces irritation in the

gastrointestinal tract and improves patient comfort. As a result, discontinuation rates decrease, and patients are more likely to continue therapy over extended periods (Maruthur et al., 2016).

Patient-Reported Outcomes (PROs)

Patient-reported outcomes (PROs) are increasingly recognized as essential indicators of treatment effectiveness and adherence. These outcomes capture patients' perspectives on satisfaction, convenience, tolerability, and overall quality of life. Literature-based evidence suggests that therapies incorporating controlled-release and microparticle systems are associated with higher levels of patient satisfaction and compliance. The integration of PROs into pharmaceutical research provides valuable insights into real-world treatment performance and helps guide the development of patient-centered drug delivery systems. By aligning clinical efficacy with patient experience, PROs contribute to more holistic and effective diabetes management strategies (Deshpande et al., 2018).

3. PHARMACEUTICAL AND CLINICAL IMPLICATIONS OF MICROPARTICLE SYSTEMS

PLGA–Metformin Systems and Adherence Outcomes

Microparticle systems based on PLGA (Poly(lactic-co-glycolic acid)) have demonstrated strong potential to improve adherence outcomes in diabetes therapy by enabling sustained drug release and maintaining therapeutic stability. When Metformin is encapsulated within PLGA matrices, it is released gradually through diffusion and polymer degradation processes, thereby ensuring prolonged drug availability in systemic circulation. This sustained release minimizes peak–trough fluctuations in plasma concentration and contributes to more consistent glycemic control. A major advantage of such systems is the reduction in dosing frequency, which directly influences patient behavior by simplifying treatment regimens. As adherence is strongly linked to regimen simplicity, the reduced need for multiple daily doses enhances compliance and long-term treatment persistence (Davis et al., 2021).

Pharmacokinetic–Behavioral Linkages

The relationship between pharmacokinetics and patient behavior is central to understanding adherence dynamics. Controlled drug release from microparticle systems stabilizes plasma drug levels, preventing sudden spikes that may lead to adverse effects and subsequent

discontinuation. Stable pharmacokinetic profiles contribute to improved tolerability and patient confidence in the therapy. Furthermore, simplified dosing regimens derived from sustained-release formulations reduce cognitive and practical burdens on patients, making it easier to maintain consistent medication intake. This linkage between optimized drug release and behavioral adherence underscores the importance of integrating pharmacological design with patient-centered considerations (Claxton et al., 2001).

Polymer Characteristics and Patient-Centric Design

The effectiveness of microparticle systems largely depends on the intrinsic properties of the polymers used. Characteristics such as molecular weight, degradation rate, and hydrophilicity influence drug release behavior and overall formulation performance. Biocompatibility and biodegradability are particularly important, as they ensure that the polymer does not induce adverse biological responses. PLGA, for instance, degrades into naturally metabolized compounds, making it suitable for repeated administration. From a patient-centric perspective, formulation design must prioritize not only pharmacokinetic efficiency but also user convenience and comfort. Tailoring polymer properties to achieve optimal release profiles and minimal side effects contributes significantly to improving adherence (Makadia & Siegel, 2011).

Safety, Acceptability, and Long-Term Use

Safety and acceptability are critical determinants of long-term medication adherence. Microparticle systems offer enhanced safety profiles due to their controlled release mechanisms and use of biodegradable materials. Patients are more likely to continue therapy when they perceive the treatment as safe and tolerable. Reduced incidence of gastrointestinal side effects, commonly associated with conventional formulations, further enhances acceptability. Long-term tolerability is especially important in chronic conditions such as diabetes, where continuous medication is required. The favorable safety perception associated with biodegradable polymers supports sustained patient engagement with therapy (Danhier et al., 2012).

Healthcare and Industrial Implications

The adoption of microparticle-based drug delivery systems has significant implications for both healthcare systems and the pharmaceutical industry. Improved adherence leads to better

disease management, which in turn reduces complications, hospital admissions, and overall healthcare costs. From an economic perspective, sustained-release formulations can be cost-effective by minimizing the need for additional medical interventions. In the industrial context, there is a growing trend toward the development of patient-centric drug delivery technologies that align with real-world therapeutic needs. Pharmaceutical companies are increasingly investing in advanced delivery systems to enhance product differentiation and meet regulatory expectations for improved patient outcomes (Hughes, 2007). These trends indicate a shift toward integrating clinical effectiveness with patient experience in drug development.

4. COMPARATIVE ANALYSIS

Conventional vs Microparticle-Based Systems

The comparative evaluation of conventional oral drug delivery systems and microparticle-based formulations indicates a clear distinction in their impact on patient adherence. Conventional systems, particularly immediate-release tablets, often require multiple daily doses, leading to inconsistent medication intake and reduced compliance. In contrast, microparticle-based systems provide controlled and sustained drug release, significantly reducing dosing frequency. This reduction simplifies treatment regimens and enhances patient adherence. Furthermore, therapeutic outcomes improve as drug plasma levels remain stable over extended periods, minimizing fluctuations that can compromise efficacy. Overall, literature synthesis consistently highlights that microparticle-based systems outperform conventional formulations in maintaining adherence and improving clinical effectiveness.

PLGA vs Other Polymer-Based Systems

Comparative insights from various studies suggest that PLGA-based systems exhibit superior performance in terms of release behavior, stability, and formulation reliability. Unlike many other polymers, PLGA offers predictable degradation kinetics, which ensures controlled and sustained drug release. Alternative polymers, such as chitosan and alginate, provide certain advantages like mucoadhesion and biocompatibility but often lack consistency in release patterns and structural stability. From a patient perspective, formulations based on PLGA tend to offer better reliability and consistent therapeutic outcomes, contributing to higher

acceptance. The reproducibility and scalability of PLGA formulations further enhance their pharmaceutical significance compared to other polymer-based systems.

Immediate-Release vs Sustained-Release Formulations

A comparison between immediate-release and sustained-release formulations reveals notable differences in adherence patterns. Immediate-release formulations require frequent dosing, which increases the likelihood of missed doses and treatment discontinuation. Sustained-release systems, including microparticle-based formulations, simplify dosing schedules by reducing the frequency of administration. This simplification plays a crucial role in improving patient compliance, particularly in chronic conditions such as diabetes. Additionally, sustained-release formulations help maintain consistent therapeutic drug levels, reducing side effects associated with peak concentrations and improving overall treatment experience.

Synthetic vs Natural Polymer Systems

Synthetic polymers such as PLGA and natural polymers like chitosan and alginate differ significantly in terms of tolerability, variability, and scalability. Synthetic polymers generally offer better control over physicochemical properties, resulting in predictable drug release and higher formulation stability. Natural polymers, while biocompatible and often more environmentally friendly, may exhibit variability due to biological sources and inconsistent structural properties. From a patient perspective, both types are generally well tolerated; however, the consistency and reliability of synthetic polymer systems tend to result in better therapeutic outcomes. Scalability also favors synthetic polymers, as they are easier to standardize for large-scale industrial production.

Cross-Study Synthesis of Adherence Determinants

The synthesis of findings across multiple studies reveals several common determinants influencing patient adherence. Key pharmaceutical factors include dosing frequency, drug release profile, formulation stability, and side-effect minimization. Behavioral factors such as ease of use, treatment convenience, and patient perception of therapy also play a crucial role. The integration of these pharmaceutical and behavioral aspects highlights that adherence is not solely dependent on drug efficacy but also on how the therapy aligns with patient needs and lifestyles. Microparticle-based systems effectively address these determinants by combining controlled release with improved tolerability and convenience.

Critical Interpretation of Literature

A critical analysis of the literature reveals both consensus and contradictions. While most studies agree on the advantages of sustained-release and microparticle-based systems in improving adherence, variations exist in reported effectiveness due to differences in study design, population characteristics, and evaluation methods. Methodological limitations such as short study durations, small sample sizes, and lack of standardized adherence metrics restrict the generalizability of findings. These inconsistencies highlight the need for standardized evaluation frameworks that integrate both clinical and patient-reported outcomes. Establishing uniform methodologies will enhance comparability across studies and support the development of more effective drug delivery systems.

Table 1: Summary of Comparative Analysis Findings on Microparticle-Based Drug Delivery Systems and Patient Adherence

Comparative Parameter	Conventional Systems	Microparticle-Based Systems	Key Observations
Dosing Frequency	High (multiple doses daily)	Reduced (once daily or less)	Lower dosing frequency improves adherence
Drug Release Profile	Immediate and fluctuating	Controlled and sustained	Stable plasma levels enhance therapeutic outcomes
Side Effects	Higher incidence due to peak levels	Reduced due to gradual release	Improved tolerability supports long-term use
Polymer Stability	Not applicable	High (especially PLGA-based systems)	Ensures consistent drug delivery
Patient Compliance	Moderate to low	High	Simplified regimens increase adherence
Formulation Reliability	Standard but limited flexibility	High with controlled systems	Advanced formulations offer better performance
Scalability	Established	High for synthetic polymers	Industrial production is feasible

Patient Acceptance	Variable	Generally higher	Convenience and comfort improve perception
--------------------	----------	------------------	--

Table 4.1 provides a consolidated summary of the comparative findings derived from the literature-based analysis. It highlights key differences between conventional drug delivery systems and microparticle-based formulations across critical parameters such as dosing frequency, drug release profile, and patient compliance. The table clearly illustrates that microparticle-based systems offer significant advantages in terms of sustained drug release, reduced side effects, and improved adherence. It also emphasizes the role of polymer stability and formulation reliability in ensuring consistent therapeutic outcomes. Overall, the table serves as a visual representation of how advanced drug delivery systems address both pharmaceutical and behavioral challenges, reinforcing their importance in modern diabetes management.

5. CONCLUSION AND RECOMMENDATIONS

Conclusion

This study has demonstrated that microparticle-based drug delivery systems had played a significant role in improving patient adherence in diabetes management. It was observed that these systems had effectively addressed key barriers associated with conventional oral therapies, particularly those related to frequent dosing and adverse effects. The sustained release characteristics of microparticle formulations had enabled more stable drug plasma levels, which had contributed to improved therapeutic consistency and reduced the likelihood of treatment discontinuation. As a result, patient compliance had shown considerable improvement, especially in long-term treatment scenarios.

The study also highlighted that PLGA-based formulations had emerged as highly effective platforms for enhancing oral anti-diabetic therapy. Their predictable degradation profile, biocompatibility, and ability to provide controlled drug release had ensured both safety and reliability in drug delivery. These properties had not only improved pharmacokinetic outcomes but had also positively influenced patient acceptance and adherence behavior. Furthermore, the findings emphasized that successful diabetes management required more than

pharmacological efficacy alone. The integration of pharmaceutical innovation with patient behavior had proven essential in designing drug delivery systems that align with real-world patient needs and preferences. This combined approach had strengthened the overall effectiveness of therapeutic interventions.

Recommendations

Formulation Design:

Future pharmaceutical development should prioritize the design of adherence-focused drug delivery systems. Emphasis should be placed on optimizing sustained-release mechanisms, reducing dosing frequency, and minimizing side effects. Formulations should be developed with a patient-centric approach, ensuring ease of administration, stability, and consistent therapeutic performance.

Clinical Practice:

Healthcare providers should incorporate sustained-release and microparticle-based formulations into standard treatment protocols for diabetes management. By adopting these advanced delivery systems, clinicians can enhance patient adherence and improve long-term treatment outcomes. Patient education regarding the benefits of such formulations should also be emphasized to support informed decision-making.

Regulatory Development:

Regulatory authorities should promote the development and approval of patient-centric drug delivery systems by establishing clear and comprehensive guidelines. These guidelines should address quality control, safety evaluation, and performance standards for microparticle-based formulations. Encouraging innovation in adherence-enhancing technologies will facilitate the translation of research findings into clinical practice.

Future Research:

Further research is required to explore long-term adherence patterns associated with microparticle-based drug delivery systems. Studies should focus on behavioral aspects of medication use and evaluate the sustained impact of controlled-release formulations over extended periods. Additionally, integrating digital health technologies such as adherence

monitoring tools and mobile health applications can provide valuable insights into patient behavior and support personalized treatment strategies.

Industrial Application:

Pharmaceutical industries should focus on developing scalable and cost-effective production techniques for microparticle-based formulations. Ensuring consistency, quality, and affordability will be essential for widespread adoption. Collaboration between industry and academic institutions can accelerate innovation and facilitate the commercialization of advanced drug delivery systems, ultimately improving accessibility and patient outcomes in diabetes care.

References

1. Brown, M. T., & Bussell, J. K. (2011). Medication adherence: WHO cares? *Mayo Clinic Proceedings*, 86(4), 304–314.
2. Claxton, A. J., Cramer, J., & Pierce, C. (2001). A systematic review of the associations between dose regimens and medication compliance. *Clinical Therapeutics*, 23(8), 1296–1310.
3. Costa, E., Giardini, A., Savin, M., Menditto, E., Lehane, E., Laosa, O., Pecorelli, S., Monaco, A., & Marengoni, A. (2019). Interventional tools to improve medication adherence: Review of literature. *Patient Preference and Adherence*, 13, 1563–1581.
4. Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012). PLGA-based nanoparticles: An overview of biomedical applications. *Journal of Controlled Release*, 161(2), 505–522.
5. Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012). PLGA-based nanoparticles: An overview of biomedical applications. *Journal of Controlled Release*, 161(2), 505–522.
6. Davis, E. M., Packard, K. A., & Hilleman, D. E. (2021). Pharmacologic management of type 2 diabetes mellitus: Available therapies. *American Journal of Health-System Pharmacy*, 77(5), 319–330.

7. Deshpande, P. R., Rajan, S., Sudeepthi, B. L., & Nazir, C. P. (2018). Patient-reported outcomes: A new era in clinical research. *Perspectives in Clinical Research*, 2(4), 137–144.
8. Hughes, D. A. (2007). Medication non-adherence in patients with chronic disease: Issues in healthcare policy. *Patient Preference and Adherence*, 1, 315–321.
9. Jimmy, B., & Jose, J. (2011). Patient medication adherence: Measures in daily practice. *Oman Medical Journal*, 26(3), 155–159.
10. Kardas, P., Lewek, P., & Matyjaszczyk, M. (2013). Determinants of patient adherence: A review of systematic reviews. *Frontiers in Pharmacology*, 4, 91.
11. Krass, I., Schieback, P., & Dhippayom, T. (2015). Adherence to diabetes medication: A systematic review. *Diabetic Medicine*, 32(6), 725–737.
12. Kumari, A., Yadav, S. K., & Yadav, S. C. (2010). Biodegradable polymeric nanoparticles based drug delivery systems. *Colloids and Surfaces B: Biointerfaces*, 75(1), 1–18.
13. Lee, J. H., Yeo, Y., & Kim, J. S. (2015). Advanced drug delivery systems for diabetes management. *Journal of Controlled Release*, 219, 2–13.
14. Makadia, H. K., & Siegel, S. J. (2011). Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. *Polymers*, 3(3), 1377–1397.
15. Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016). Diabetes medications as monotherapy or metformin-based combination therapy. *Annals of Internal Medicine*, 164(11), 740–751.
16. McCreight, L. J., Bailey, C. J., & Pearson, E. R. (2016). Metformin and the gastrointestinal tract. *Diabetologia*, 59(3), 426–435.
17. Osterberg, L., & Blaschke, T. (2005). Adherence to medication. *New England Journal of Medicine*, 353(5), 487–497.

18. Peppas, N. A., Bures, P., Leobandung, W., & Ichikawa, H. (2016). Hydrogels in pharmaceutical formulations. *European Journal of Pharmaceutics and Biopharmaceutics*, 50(1), 27–46.
19. Polonsky, W. H., & Henry, R. R. (2016). Poor medication adherence in type 2 diabetes: Recognizing the scope of the problem. *Diabetes Care*, 39(6), 905–909.
20. Shrivastava, S. R., Shrivastava, P. S., & Ramasamy, J. (2013). Role of self-care in management of diabetes mellitus. *Journal of Diabetes & Metabolic Disorders*, 12(1), 14.
21. Vllasaliu, D., Fowler, R., & Stolnik, S. (2014). PEGylated nanomedicines: Recent progress and remaining concerns. *Expert Opinion on Drug Delivery*, 11(1), 139–154.